Tumor cells
Tumor cells are the malignant cellular component of a cancerous tumor.
Tumor cells are the malignant cellular component of a cancerous tumor. They arise from genetic and epigenetic alterations that disrupt normal control of proliferation, survival, differentiation, and interaction with the surrounding tumor microenvironment. As a result, tumor cells can acquire properties such as unchecked growth, resistance to apoptosis, immune evasion, invasive behavior, and drug resistance. Their biology is strongly shaped by signals from the tumor microenvironment, including cytokines, metabolic stress, and interactions with stromal cells, immune cells, and extracellular matrix.
In biomedical research, tumor cells are a central therapeutic target for chemotherapy, photochemotherapy, photothermal therapy, immunotherapy, and nanomedicine-based drug delivery. Many recent studies have focused on selectively directing agents to tumor cells, reversing chemoresistance, or inducing immunogenic cell death and cytotoxicity. In these contexts, pathways involving transforming growth factor, reactive oxygen species, glutathione metabolism, and immune checkpoints can influence how tumor cells respond to treatment and how effectively the tumor can be controlled.
Where the papers sit
21 papers from the last 6 months study tumor cells directly · updated from PubMed 3 Nov 2026
Study type 0 clinical trials · 3 human data · 16 preclinical · 2 unclassified
Themes one subject · 1 paradigm shift · 1 new direction
Those 21 are all about one subject.
-
Experimental Cancer Therapeutics
Targeted delivery, immune activation and catalytic nanomedicine are being combined to improve cancer treatment. Iron deprivation, ferroptosis, sonodynamic or photothermal effects, and chemotherapy recur as ways to overcome drug resistance. Vaccine strategies use nonself peptides, AIRE conditioning, poly(I:C)/QS-21 and PD-1 blockade to strengthen tumor-specific immunity. Biomarker work on UBC9, PI3K, transcriptomic patterns and plasma-cell antibodies points toward patient selection, but the set offers no single established clinical direction.
Stromal cells can be the decisive source of tumor chemoresistance rather than merely supporting tumor-cell-intrinsic resistance
The dual-cargo micelles for drug-resistant breast cancer and the mitophagy-competent cancer-associated fibroblast study in pancreatic cancer show, independently, that resistant tumor cells cannot be treated as the sole locus of chemotherapy failure. In breast cancer, CAF depletion disrupted metabolic symbiosis and biomechanical barriers, while in pancreatic cancer, ZEB1-driven CAF mitophagy increased nucleotide secretion that both blocked gemcitabine incorporation and supplied pyrimidine substrates to cancer cells. The therapeutic implication is that overcoming resistance requires disabling stromal programs alongside tumor-cell targets, rather than intensifying tumor-cell-directed therapy alone 42572978Aug 42202065May.
Tumor-cell motility is presented as a regulator that can reorganize and weaken antitumor immune spatial patterns
The tumor-immune reaction-diffusion model integrated with spatial transcriptomics assigns persistent and resistant tumor cells an active spatial role beyond being targets of immune attack or sources of prognostic biomarkers. It predicts that increased tumor-cell movement disrupts immune-dominant spot patterns, which otherwise produce stronger tumor suppression than stripe patterns, and reports corresponding pattern differences in three tumor cohorts. This makes tumor-cell motility a determinant of immune architecture and treatment-relevant immune dominance, suggesting that controlling movement could preserve effective spatial antitumor immunity 42721081Sep.
Papers
The 21 papers from the last 6 months that study tumor cells directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Experimental Cancer Therapeutics (21)
- Ionic liquid-mediated cellular loading for whole tumor cell vaccines. Proceedings of the National Academy of Sciences of the United States of America · 28 Oct 2026 PMID 42949972
- Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides. ACS applied bio materials · 2 Oct 2026 PMID 42826501
- Integrating tumor-immune mechanistic modeling with transcriptomics reveals pattern-driven prognostic biomarkers in tumors. Proceedings of the National Academy of Sciences of the United States of America · 10 Sept 2026 PMID 42721081
- Iron-Deprivation Liposomes for Cancer Therapy. Angewandte Chemie (International ed. in English) · 9 Sept 2026 PMID 42711711
- Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome. Cancer immunology research · 26 Aug 2026 PMID 42644627
- Endowing Centrosymmetric Oxides with Effective Piezoelectricity via Oxygen Vacancy Engineering and Single-Atom Anchoring for Multicatalytic Sono-Immunotherapy. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619089
- Tailoring Crystallization Modulators for the Facile Synthesis of One-Dimensional Covalent Organic Frameworks to Boost Ultrasound-Triggered Pyroptosis and Immunotherapy. Angewandte Chemie (International ed. in English) · 19 Aug 2026 PMID 42615286
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- Biomimetic Synthesis of Multinuclear Metal-Oxo Bridges Under Mild Aqueous Conditions for Catalytic Cancer Therapy. Angewandte Chemie (International ed. in English) · 6 Aug 2026 PMID 42559927
- UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 29 Jul 2026 PMID 42522541
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- In Situ Transferrin-Mediated Sandwich-like Targeting with Engineered Ginger-Derived Extracellular Vesicles for Precision Oral Chemotherapy of Colorectal Cancer. ACS nano · 22 Jul 2026 PMID 42486784
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS applied bio materials · 20 Jul 2026 PMID 42474418
- Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
- Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
- Photoelectric Therapy Needle-Combined ICG-Cu(II)-AIBI Infinite Coordination Polymer Nanoparticles for Free Radical Spatiotemporal-Matched Photodynamic-Thermodynamic Tumor Synergistic Therapy. ACS applied materials & interfaces · 15 Jun 2026 PMID 42295973
- Engineered maleoyl-chitosan grafted with oligopeptides nanogels with dual-mode mobility toward melanoma therapy. International journal of biological macromolecules · 2 Jun 2026 PMID 42229647
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
- In Situ Electroactive Bacteria-Activated Nanozyme for Amplifying Chemodynamic Therapy of Solid Tumors. Nano letters · 22 May 2026 PMID 42170851
- "Artificial platelet injection system": a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation. Bioactive materials · 8 May 2026 PMID 42100675
By study type
Human data, design not indexed (3)
- Integrating tumor-immune mechanistic modeling with transcriptomics reveals pattern-driven prognostic biomarkers in tumors. Proceedings of the National Academy of Sciences of the United States of America · 10 Sept 2026 PMID 42721081
- Tailoring Crystallization Modulators for the Facile Synthesis of One-Dimensional Covalent Organic Frameworks to Boost Ultrasound-Triggered Pyroptosis and Immunotherapy. Angewandte Chemie (International ed. in English) · 19 Aug 2026 PMID 42615286
- UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 29 Jul 2026 PMID 42522541
Preclinical: animal, cell and lab studies (16)
- Ionic liquid-mediated cellular loading for whole tumor cell vaccines. Proceedings of the National Academy of Sciences of the United States of America · 28 Oct 2026 PMID 42949972
- Enhancing Tumor Immunogenicity through Hyaluronic Acid-Mediated Delivery of Nonself Antigenic Peptides. ACS applied bio materials · 2 Oct 2026 PMID 42826501
- Cancer Immunotherapy Using AIRE Conditioning of the Tumor Epitopeome. Cancer immunology research · 26 Aug 2026 PMID 42644627
- Endowing Centrosymmetric Oxides with Effective Piezoelectricity via Oxygen Vacancy Engineering and Single-Atom Anchoring for Multicatalytic Sono-Immunotherapy. Journal of the American Chemical Society · 20 Aug 2026 PMID 42619089
- Dual-cargo polymeric micelles with tumor-cell/stroma dual-targeting for synergistic eradication of drug-resistant breast cancer. Biomaterials science · 10 Aug 2026 PMID 42572978
- Biomimetic Synthesis of Multinuclear Metal-Oxo Bridges Under Mild Aqueous Conditions for Catalytic Cancer Therapy. Angewandte Chemie (International ed. in English) · 6 Aug 2026 PMID 42559927
- Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies. Cancer cell · 27 Jul 2026 PMID 42508408
- In Situ Transferrin-Mediated Sandwich-like Targeting with Engineered Ginger-Derived Extracellular Vesicles for Precision Oral Chemotherapy of Colorectal Cancer. ACS nano · 22 Jul 2026 PMID 42486784
- A poly(I:C)/QS-21-based in situ vaccine synergizes with anti-PD-1 therapy to overcome tumor immunoresistance. Cell reports. Medicine · 22 Jul 2026 PMID 42486097
- Tumor Microenvironment-Responsive Biomimetic Self-Assembled Nanomedicine for Precision Combination Therapy against Triple-Negative Breast Cancer. ACS applied bio materials · 20 Jul 2026 PMID 42474418
- Hyaluronic acid-modified nanoparticles for chemo/sonodynamic therapy: Maximizing antitumor efficacy through the induction of ferroptosis and apoptosis. International journal of biological macromolecules · 5 Jul 2026 PMID 42402299
- Fe3+-responsive aggregable gold nanoplatform enables siRNA-mediated chemoresistance reversal and combined photothermal-temozolomide therapy for glioblastoma. Acta biomaterialia · 18 Jun 2026 PMID 42315000
- Photoelectric Therapy Needle-Combined ICG-Cu(II)-AIBI Infinite Coordination Polymer Nanoparticles for Free Radical Spatiotemporal-Matched Photodynamic-Thermodynamic Tumor Synergistic Therapy. ACS applied materials & interfaces · 15 Jun 2026 PMID 42295973
- Engineered maleoyl-chitosan grafted with oligopeptides nanogels with dual-mode mobility toward melanoma therapy. International journal of biological macromolecules · 2 Jun 2026 PMID 42229647
- Mitophagy-Competent Cancer-Associated Fibroblasts Fuel Chemoresistance by Rewiring Pyrimidine Metabolism in Pancreatic Cancer. Cancer research · 27 May 2026 PMID 42202065
- In Situ Electroactive Bacteria-Activated Nanozyme for Amplifying Chemodynamic Therapy of Solid Tumors. Nano letters · 22 May 2026 PMID 42170851
Unclassified: not yet indexed with MeSH (2)
- Iron-Deprivation Liposomes for Cancer Therapy. Angewandte Chemie (International ed. in English) · 9 Sept 2026 PMID 42711711
- "Artificial platelet injection system": a plug-and-play platelet-based lysosome-targeting chimera for targeted protein degradation. Bioactive materials · 8 May 2026 PMID 42100675
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-08-19. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.